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Abstract
Cadmium is a toxic heavy metal ubiquitously present in the environment and subsequently in the human diet. Cadmium
has been proposed to disrupt the endocrine system, targeting in particular the estrogen signaling pathway already at
environmentally relevant concentrations. Thus far, the reports on the binding affinity of cadmium towards human estrogen
receptor alpha (hERa) have been contradicting, as have been the reports on the in vivo estrogenicity of cadmium. Hence,
the mode of interaction between cadmium and the receptor remains unclear. Here, we investigated the interaction
between cadmium and hERa on a molecular level by applying a novel, label-free biosensor technique based on
reflectometric interference spectroscopy (RIfS). We studied the binding of cadmium to hERa, and the conformation of the
receptor following cadmium treatment. Our data reveals that cadmium interacts with the ligand binding domain (LBD) of
the ERa and affects the conformation of the receptor. However, the binding event, as well as the induced conformation
change, greatly depends on the accessibility of the cysteine tails in the LBD. As the LBD cysteine residues have been
reported as targets of post-translational modifications in vivo, we present a hypothesis according to which different cellular
pools of ERa respond to cadmium differently. Our proposed theory could help to explain some of the previously
contradicting results regarding estrogen-like activity of cadmium.
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Introduction
Cadmium is a heavy metal with no known beneficial
physiological function. It is ubiquitously present in Earth’s crust,
from where it is released by volcanic activity, mining, and use of
phosphate fertilizers and fossil fuels. Plants take up cadmium from
the soil and form the major source of cadmium intake in non-
smoking, non-occupationally exposed populations [1]. The
average daily intake of cadmium through diet is approximately
10–20 mg, which is close to the recently revised tolerable weekly
intake of 2.5 mg/kg set by the European Food Safety Authority
[1]. Chronic exposure to cadmium causes damage to the kidneys
and bone, increases the risk of various cancers, and disrupts
reproductive functions in both female and male [2,3,4]. The
Interactional Agency for Research on Cancer has classified
cadmium as a group I human carcinogen [5]. More recently,
studies demonstrating estrogen-like activity of cadmium have
raised concerns and led to a classification of cadmium as an
endocrine disrupter [6,7,8].
The estrogen receptors ERa and ERb are nuclear hormone
receptors that regulate gene expression in response to the female
sex steroids estrogens. When the cognate ligand 17b-estradiol (E2)
binds to the ligand binding pocket within the ERaLBD, it interacts
with specific amino acid residues (glu353, arg394, and his524)
leading to a conformational change and the formation of the
activation function 2 (AF-2), which is an interaction site for co-
activators [9]. The recruitment of co-activators bridges the receptor
to the basal transcription machinery and allows the regulation of
transcription. Alternatively, the activation of ERa can lead to rapid,
extranuclear and thus non-genomic effects like release of secondary
messengers and activation of kinases [10]. The mechanisms of the
extranuclear activities of the ERs remain less well understood than
the genomic activities. Nevertheless, inappropriate regulation of ER
activity by environmental endocrine disrupters is believed to be a
factor behind the increasing incidence of hormonal cancer in
industrialized countries. For example, cadmium exposure is linked
to the risk of endometrial and breast cancer in humans [11,12].
These epidemiological connections to increased risk of hormonal
cancers in humans render the understanding of the endocrine
disruptive mechanisms of cadmium very important.
In mammalian cell culture, cadmium induces the expression of
estrogen target genes, triggers activation of cytoplasmic kinases,
and promotes proliferation of estrogen responsive cell lines
[7,8,13,14,15,16,17,18,19], suggesting that cadmium promotes
an agonist conformation of the ER and activates both genomic
and non-genomic estrogen signaling. However, these effects are
not observed in all studies [19,20,21,22]. Similarly, in rodents
cadmium promotes uterine growth, the hallmark of estrogen
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binding of cadmium to hERa has been studied in two independent
reports. Stoica et al. reported cadmium as a strong ligand for the
hERa (dissociation constant KD=5*10
210 M) [8], while Rider et
al. classified cadmium as a non-binder [8,27].
In order to help explain these contradictory findings, we
decided to apply a novel biosensor technique to study the binding
of cadmium to hERa and the conformational consequences of the
interaction. Our methodology is based on RIfS, and it represents a
label free, time-resolved method for the study of specific
interactions between biomolecules. The platform has successfully
been applied to ERa before to study the binding to ligands
[28,29], DNA [30], and co-activators [31]. The principle of the
RIfS assay relies on measuring the change in optical thickness of
thin transducer chips that are coated with suitable biomolecules
(Figure 1). We applied two different chips in the current study that
we have recently thoroughly characterized: one coated with a
derivative of the ERa ligand estrone (E1) [29] and another with a
peptide that binds to the agonist conformation of ERaLBD [31].
Materials and Methods
Materials
RIfS-transducer chips of 1 mm thick D263 glass-substrate with
a first layer of 10 nm Ta2O5 and a layer of 330 nm SiO2 on top
were obtained from Schott AG (Mainz, Germany). Common
organic compounds and biochemicals were purchased either from
Fluka (Neu-Ulm, Germany), SigmaAldrich (Deisenhofen, Ger-
many) or Merck (Darmstadt, Germany). 3-Glycidyloxypropyl-
trimethoxysilane and diisopropylcarbodiimide were purchased
from Fluka, di-amino-poly(ethylene glycol) (DAPEG) with a
molecular mass 2000 Da from Rapp Polymere (Tu ¨bingen,
Germany), and d-biotin and 2-(1H-benzotriazol-1-yl)-1,1,3,3-
tetramethyluronium tetrafluoroborate from Sigma-Aldrich. Es-
trone-17-N-carboxymethyloxime (E1-17-CMO) was kindly pro-
vided by Dr. Ram Abuknesha (King’s College London, UK).
Purified (single band on native-PAGE) carboxymethylated
hERaLBD (CM-hERaLBD) (30 kDa) was kindly provided by
KaroBio AB (Stockholm, Sweden). Biotinylated peptide a/b I with
the amino acid sequence Ser-Ser-Asn-His-Gln-Ser-Ser-Arg-Leu-
Ile-Glu-Leu-Leu-Ser-Arg was purchased from Thermo Scientific
(Ulm, Germany) and the recombinant full length hERa (66.4 kDa)
from Mobitec (Go ¨ttingen, Germany).
Preparation of the transducer chips
The RIfS transducer chips were cleaned, activated and
silanized, and diamino-poly(ethylene glycol) was then immobilized
to the surface as described previously [29,31].
The chips coated with E1-17-CMO were prepared essentially as
described in [29]. Shortly, E1-17-CMO was dissolved in
dimethylsulfoxide (DMF), N,N-diisopropylethylamine was added,
and the mixture was pipetted onto a DAPEG transducer and
sandwiched with another DAPEG transducer. The sandwich was
then incubated in a DMF-saturated atmosphere for 6 h and finally
rinsed with DMF and water.
The chips coated with a/b I peptide were prepared like
described before [31]. Shortly, biotin was immobilized to the
surface via 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium
tetrafluoroborate activation. Then streptavidin solution was
flushed over the sensor surface, followed by biotinylated a/b I
peptide solution.
A detailed reaction scheme of the surface chemistry is provided
in Figure S1.
Figure 1. The principle of the RIfS ligand binding assay. (A) The
RIfS ligand binding assay relies on derivatives of the specific ERa ligand
E1-17-CMO that are covalently bound to the sensor chip surface. White
light is illuminated into the system, and it reflects from the different
boundaries of the multilayered chip. In case protein binds to the
surface, the reflectivity is changed and the optical thickness,
determined from the interference spectra, increases. (B) The depen-
dence of the optical thickness of estrogen content in the sample. In
case there are no ERa ligands present in the sample, the receptor is free
to bind the surface, and the optical thickness of the surface is high (the
situation boxed with green). If there are ERa ligands present, they
prevent the receptor from binding the surface leading to decreased
optical thickness (the situation boxed with yellow), until all receptor is
saturated with the ligand and it can no longer bind the surface (the
situation boxed with red).
doi:10.1371/journal.pone.0023048.g001
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Stock solutions of 1 mg/mL of E2 and 4-hydroxy-tamoxifen (4-
OHT) were prepared in dimethylsulfoxide and stored at 4uCi n
the dark until use. CdCl2 was stored as 0.1 M stocks in the freezer.
Different concentrations of CdCl2 were freshly prepared by
dilution with Milli-Q water.
The reactions between ERa and ligands were carried out in a
binding inhibition test format, where the receptor is pre-incubated
with the ligands before the mixture is injected to the RIfS setup.
All incubations were carried out for 60 min at 4uC in the dark.
Ligand binding assay. In ligand binding assays, a constant
concentration of the receptor (548 nM for hERa and 208.3 nM
for CM-hERaLBD) was incubated with different concentrations of
CdCl2 (2.9 nM–285.7 mM). These mixtures were then investigated
via RIfS using E117-CMO modified transducers. When E2 was
titrated to CM-hERaLBD with or without 5 mM CdCl2 the
concentration of E2 was varied between 3.3 nM E2 and 1.3 mM
E2.
A detailed scheme for the binding assay is provided in Figure
S2.
Conformation assay. In the conformation assay, constant
concentrations of receptors (3.3 mM) were incubated with 3.3 mM
CdCl2, 9 mg/L E2 (33 mM), or 9 mg/L 4-OHT (24 mM). These
mixtures were then investigated via RIfS using a/b I modified
transducers.
A detailed scheme for the conformation assay is provided in
Figure S3.
The principle of the RIfS-based ligand binding assay
The RIfS setup consists of a halogen white-light source and a Y-
optical fiber, which guides the light to the transducer chip. The
reflected light is travels through the same optical Y-fiber to a diode
array spectrometer (Spekol-1100, Analytik Jena, Germany). The
liquid handling system consists of a Hamilton dilutor Microlab
(Hamilton, Switzerland) with two syringe pumps and a 4-way
valve. Data acquisition and evaluation was performed using
internal software.
The binding of the receptor to the surface was monitored for
250 s after a 100 s baseline period, followed by a 300–600 s
dissociation phase and a regeneration step with 6 M guanidi-
niumhydrochloride pH 2 and a 240 s baseline period. The optical
thickness was followed by recording interference of white light
reflected at the interfaces of the chip by a diode array
spectrometer. Binding curves were recorded as changes of the
apparent optical thickness [nm] versus time [s]. All measurements
were carried out in 500 mM Tris buffer containing 100 mM KCl
with a pH of 7.4 at room temperature (,25uC). The assays were
repeated three times and in figures mean optical thickness with
standard deviation is presented.
The concentration of the receptor in the reaction mixture was
adjusted so that the binding signals revealed a linear shape. By
providing an excess of possible interaction partners on the surface,
it could be ensured that every free receptor molecule could bind to
a superior number of free immobilized ligands on the surface.
Under these conditions, the obtained sensor signal is dependent on
the diffusion of receptors to the sensor surface expressed by Fick’s
law,
JD~{D: dc
dx
~{D: c
d
where JD is the diffusion flux, D the diffusion coefficient of the
biomolecules in solution, c the concentration of these biomole-
cules, and d the thickness of the diffusion layer. The slope of the
binding curve is proportional to the concentration of free receptor
in solution. Assuming that Cd binds to the same binding pocket as
the steroidal estrogens, such as E2, the equation for the affinity
constant deducted from the mass equation results in the following
formula,
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where cRL is the concentration of the receptor-ligand complex, cR
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The concentration of free receptor can therefore be expressed as
cR~cR,0{cRL
Knowing this relation between the equations it is possible to
determine the affinity constant directly as a parameter of the fit
function.
Results and Discussion
Measurement of biomolecular interactions using RIfS
Biosensors represent relatively young analytical methodology,
but have proven to be very powerful in combination with nuclear
receptors [32]. Among the large group of biosensors, the label-free
techniques provide particular advantages. Their ability to trace
biomolecular interactions in a time-resolved manner without a
need for labeling minimizes the possibility of artifacts. In addition,
in contrast to other more popular biosensors, such as surface
plasmon resonance, RIfS uses glass instead of metal films as
transducers. In other words, the RIfS surface chemistry does not
rely on thiol/gold chemistry which is a great advantage in the
present study considering the possible interaction between thiol-
containing polymers and cations such as cadmium.
We applied two different sensor chips in our studies, one coated
with the ER specific ligand E1-17-CMO, and one coated with a
peptide called a/b I that binds to the AF-2, i.e. the agonist
conformation of ERaLBD. Both assay formats have been
developed and characterized by us [29,31]. The principle of the
RIfS based binding assay is presented in Figure 1 (and discussed in
detail e.g. in [33]). We first pre-incubated the receptor protein in
solution with CdCl2 or control ligands, and then introduced the
mixture to the sensor chips. The binding of the receptor to the
surface was monitored over time with the help of white light
passing through the chip, and the reflected light was recorded with
a diode array spectrometer. Association (and dissociation) of the
receptor to the surface changes the reflectivity of the multilayered
chip, which is seen as changes in the interference spectrum, and
can be calculated as optical thickness of the chip (Figure 1A).
Using the curve showing the change in optical thickness over time
we then calculate the relative slope, which is simply defined as the
change of optical thickness over time in a given treatment. Finally
we normalize the results in one series of experiments to the highest
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containing untreated receptor. For example, in case cadmium does
not bind to ERa ligand binding pocket, the receptor is free to bind
to the E1-17-CMO coated surface, which we observe as an
increase in the optical thickness, which gives a high relative slope
(Figure 1B). Similarly, in the conformation assay, if cadmium
induces an agonist conformation, the receptor will bind to the a/b
I coated surface, and the optical thickness is increased.
Binding of cadmium to hERa
Currently, there is little doubt that cadmium has an effect on the
estrogen signaling. However, it is striking that the nature of the
reported effects varies from strong agonist to antagonist in the
different model systems [6,8,21,22,26,27]. To understand these
inconsistencies, it is essential to know how exactly cadmium
interacts with the ER. To our knowledge, only two studies have
assessed the binding of cadmium to hERa: Stoica et al. classified
cadmium as a strong agonist while Rider et al. concluded that
cadmium is a non-binder that, however, disrupts the binding
properties of E2 [8,27]. In both reports, cell based and cell free
radioligand binding assays were utilized side by side. To gain new
insights into the binding mechanism, we applied the RIfS
methodology developed in our laboratory. We incubated different
concentrations of CdCl2 with a constant concentration of
recombinant full length hERa for 1 h, after which we quantified
the relative amount of free ERa with the E1-coated RIfS sensor
chips. Our results show that CdCl2 dose-dependently decreases the
optical thickness of the surface (Figure 2A). In other words,
cadmium binds to hERa. In the cell free binding assay format,
both Rider et al. and Stoica et al. have reported similar results:
CdCl2 prevents steroidal estrogens from binding to hERa. Based
on our binding curve, the dissociation constant for cadmium was
KD=6.1*10
27 M, which suggests strong but weaker interaction
than reported by Stoica et al. (KD=5*10
210 M). The difference
between the values could partly depend on the different
experimental methods. While Stoica et al. utilized radioligand
displacement assay, our platform is label-free and detects the
binding event in real time. Other additional minor details, such as
buffer composition, incubation times and reaction temperatures
could further affect the result. Although the two KD values differ,
they both suggest that cadmium has marked affinity towards the
hERa.
Although Rider et al. also observed interaction between
cadmium and hERa in their cell free assay, they could not
calculate a dissociation constant, because the data did not fit the
one-site competitive model. In fact, also Stoica and coworkers
noted that the binding of cadmium to hERa displayed non-
competitive features. In agreement with these observations, we
also observe that the shape of our data fits poorly to the binding
curve (Figure 2A). The RIfS binding assay assumes competitive
binding of ligands to the same ligand binding cavity following the
mass equation [R]+[L]«[RL]. Therefore, our data could reflect
non-competitive binding mode in agreement with the earlier
reports [8,27]. The non-competitive binding mode, and subse-
quent difficulty to fit the data into a one-site model, could further
explain the difference in the KD value in our work compared to
that of Stoica et al.
We next determined the effect of cadmium on the conformation
of hERa. We incubated hERa with vehicle (buffer without ligand
or CdCl2 but with corresponding amount of solvent), CdCl2,E 2,
the antiestrogen 4-OHT, or combinations of CdCl2 with E2 or 4-
OHT. As expected, E2 treated hERa bound to the a/b I coated
surface, indicating an agonist conformation, while vehicle and 4-
OHT treated hERa did not (Figure 2B). To our surprise, CdCl2
treated hERa did not bind to the surface. Moreover, when hERa
was co-incubated with E2 and CdCl2, it no longer bound to the
surface (Figure 2B), indicating that cadmium destroys E2 induced
agonist conformation of ERa.
In summary, these results suggest that cadmium binds to hERa
with high affinity in a non-competitive manner without inducing
an agonist conformation, and that cadmium disrupts the agonist
conformation induced by E2. Based on these observations, it is
more likely that cadmium would trigger antiestrogenic effects in
vivo than estrogen agonist effects. Indeed, some reports in the
literature support this hypothesis. Silva et al. did not observe effects
on estrogen-dependent breast cancer cell proliferation with
cadmium alone, but in the presence of E2 cadmium inhibited
the proliferation [22]. Similar results were reported in yeast hERa
transactivation assays [21,22]. Furthermore, three independent in
vivo studies suggest that cadmium does not promote uterine growth
in rodents, suggesting lack of estrogen activity [23,25,34].
Binding of cadmium to hERa with protected cysteine
residues
Although the above results gain some support from the
literature, we do realize that they contradict several other
publications reporting estrogen-like effects for cadmium
[6,7,8,13,14,15,16,17,18,23,24]. We were concerned that the high
concentration of preservatives present in the commercial ERa
preparation might have interfered with our assay. According to
our calculations, the 537 nM hERa solution used in our assay
contained a total concentration of 343 mM of ethylenediamine-
tetraacetic acid and dithiothreitol - both well known to complex
Cd
2+. Hence, we wanted to repeat the assays without preserva-
tives. However, native ERa quickly destabilizes in the absence of
additives due to unprotected cysteine residues. In order to solve
this problem, we chose to use an hERa preparation consisting of
the LBD (amino acids 301–553) with carboxymethylated cysteine
residues [9]. This receptor variant is expected to maintain its
normal ligand binding properties, as none of the LBD cysteine
residues are in direct contact with the ligand [9]. In fact, we have
previously utilized this receptor in the RIfS binding assay without
problems [29].
We repeated the ligand binding and conformational assays
using CM-hERaLBD instead of full length hERa. Unexpectedly,
cadmium did not affect the binding of CM-hERaLBD to the
sensor surface (Figure 3A). In the case of full length hERa,
300 mM CdCl2 completely blocked the receptor from binding to
the surface (Figure 2A), but in the case of the CM-hERaLBD, the
same concentration had no impact on the receptor, and with a 10-
fold higher concentration only a minor reduction in the optical
thickness was observed (Figure 3A). To control that the batch of
CM-hERaLBD used in the assay functioned as it should, we
measured the binding affinity of E2 to it. The obtained binding
curve displayed a good fit (Figure 4, black curve) and the
calculated KD value of 2.0*10
210 M is in good agreement with
reported values for full length, unprotected hERa [8], demon-
strating that the batch of CM-hERaLBD at hand behaves like the
native receptor. To further test the effect of cadmium on this
receptor, we repeated the binding assay with E2 in the presence of
cadmium. The E2 binding curves were essentially identical in the
presence and absence of CdCl2, indicating that cadmium does not
affect the binding of E2 to the CM-hERaLBD (Figure 4). These
observations suggest that the LBD cysteine residues may have a
central role in the binding of cadmium to hERa.
In addition to the protected cysteine residues, the CM-
hERaLBD differs from the full length ERa in one more important
aspect: it lacks the domains outside the LBD. The lack of the N-
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impact on the behavior of the receptor in our assay. Although both
receptors variants we use behave normally in response to E2, the
possibility remains that unorthodox ligands such as cadmium have
a binding mode so distinct, that multiple domains are involved.
The impact of cadmium on the DNA binding domain has been
addressed before. Exchanging the zinc finger Zn
2+ ions with Cd
2+
has no functional consequence in terms of ERa DNA binding and
transcriptional activity [35,36]. We find it therefore unlikely that
the presence or absence of this domain in our assay causes the
dramatic change in the affinity of the receptor towards cadmium.
The N-terminal A/B domain harbors the ligand independent
activation function 1 (AF-1) that contributes to ER activity. Upon
ligand binding, AF-1 and AF-2 can act together to synergistically
boost ERa activity [37], and on the other hand, growth factors can
activate ER in the absence of ligands through phosphorylation of
Figure 2. Effect of cadmium on hERa. (A) The binding of cadmium to hERa was studied by incubating different concentrations of CdCl2 (2.9 nM–
285.7 mM) with a constant concentration (cR 548 nM) of hERa. The mixtures were then guided to the sensor surface and the optical thickness
monitored. Cadmium dose dependently reduces the thickness, indicating that it binds to hERa. The affinity constant (KA) is given as a fit-parameter
while O is an offset allowing the fit to be adjusted in y-axis direction. (B) The conformation of hERa was assessed after the receptor was incubated
with vehicle, CdCl2,E 2, 4-OHT, CdCl2+E2, or CdCl2+4-OHT. The average binding curves (recorded for 700 sec) of three independent assays is shown
with the standard deviation depicted as dotted lines. Only E2 alone triggered an agonist conformation recognized by the surface. Cadmium alone and
in combination with other ligands prevented the formation of agonist conformation.
doi:10.1371/journal.pone.0023048.g002
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and AF-2 involve co-regulator proteins that bridge these domains
together, and the ligand independent activation through AF-1
relies on kinase activity. Our experimental setup does not contain
co-regulators or kinases, and therefore we think that it is unlikely
that the absence of AF-1 in the CM-hERaLBD is the reason for
the discrepancy between the full length and truncated receptor
affinities towards cadmium. It is more likely that this difference is
due to the availability of the cysteine tails in the LBD, which have
been shown to be crucial for cadmium-hERa interaction by other
too [8,39].
We further tested the effect of cadmium on the carboxymethy-
lated receptor in the conformation assay. As expected, E2 induced
agonist conformation while vehicle and 4-OHT did not
(Figure 3B). However, to our great surprise, CdCl2 had marked
effects on the conformation of the CM-hERaLBD. The binding
curves show that the presence of CdCl2 in the reaction mixtures
promotes the formation of the agonist conformation of the
receptor in all environments: alone, in the presence of an agonist
(E2), and in the presence of an antagonist (4-OHT) (Figure 3B). In
summary, these observations suggest that cadmium does not bind
to CM-hERaLBD in a manner that would prevent binding of E2
Figure 3. Effect of cadmium on CM-hERaLBD. (A) The binding of cadmium to CM-hERaLBD was tested by incubating different concentrations of
CdCl2 (2.9 nM–285.7 mM) with a constant concentration of the receptor (208.3 nM). The data could not be fitted to a binding curve due to the
absence of effects on the optical thickness. (B) To determine the conformation, CM-hERa-LBD was incubated with vehicle, CdCl2,E 2, 4-OHT, CdCl2+E2,
or CdCl2+4-OHT and guided to the a/b I coated sensor surface. The average binding curves (recorded for 900 sec) of three independent assays is
shown with the standard deviation depicted as dotted lines. CdCl2 promoted the formation of the agonist conformation of the LBD alone as well as in
combination with E2 and 4-OHT.
doi:10.1371/journal.pone.0023048.g003
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affect the conformation of the receptor. It seems as if cadmium,
working outside the ligand binding pocket in the ERaLBD, can
pull the receptor towards an active conformation. This would
predict estrogen-like activities for cadmium in biological systems.
Indeed, several studies have suggested that cadmium promotes
estrogen signaling in cell culture and in experimental animals
[6,7,8,13,14,15,16,17,18,23,24].
In conclusion, carboxymethylation of the cysteine residues in
the LBD of hERa did not change the behavior of the receptor
towards E2, but dramatically altered the behavior towards CdCl2.
It is unlikely that these differences depend on the additives present
in the commercial full length hERa, or domains outside the LBD.
Instead, the results suggest fundamental differences in the binding
mechanism between E2 and cadmium. Cadmium can coordinate
with several amino acid tails, and a model has previously been
proposed where cadmium interacts with cys381, cys447, glu523,
his524 and asp538 in the hERa LBD [39]. The fact the mere
carboxymethylation of the cysteine residues had such a great effect
in our assays further emphasizes the role of these residues.
A working hypothesis
The data presented here suggests that cadmium may interact
with hERa in different manners depending on the state of the
cysteine residues in the LBD of the receptor. The two models, one
suggesting antagonistic and the other agonistic activity, both gain
support from the literature. The burning question now is, whether
both models could function in biological systems. In other words,
can the state of the cysteine residues in the ERa LBD be affected
in living cells?
The properties of many proteins are modified by post-
translational modifications, where amino acid tails are for instance
phosphorylated, sumoylated, or acetylated [40]. Various post-
translational modifications have been reported to affect ERa, and
although most of them are centered around the variable A/B
domain in the N-terminus of the protein [41], the cys447 in the
LBD is a target of palmitoylation [42]. Palmitoylation is a
mechanism to associate proteins to cell membranes. Interestingly,
cadmium has been shown to activate markers of membrane
associated estrogen signaling in breast cancer cell lines in vitro as
well as in rodents in vivo [14,15,24,34]. The cysteine residues could
also be modified in redox processes, a phenomenon that has so far
been studied only in the DNA binding domain of ERa [43].
Based on our results, we have formulated a working hypothesis
where the effect of cadmium on estrogen signaling is a net result of
different cellular pools of ERa responding to this heavy metal
differently (Figure 5). The ERa cysteines could be affected for
instance by oxidative stress (that cadmium can cause) or post-
Figure 4. Effect of cadmium on E2 interaction with the CM-
hERaLBD. The binding of E2 to CM-hERaLBD in the presence and
absence of CdCl2 was studied by incubating different concentrations of
E2 (ranging from 3.3 nM to 330.4 nM) with a constant concentration
(208.3 nM) of the receptor in the absence (black curve) or presence (red
curve) of 5 mM CdCl2.E 2 dose dependently reduces optical thickness,
and the presence of cadmium in the incubation solution did not alter
the results.
doi:10.1371/journal.pone.0023048.g004
Figure 5. A working hypothesis. (A) Different cellular pools of ERa
might have different reactivity towards cadmium depending on the
cysteine residues (marked with a stick). The cysteine residues may
become unavailable for interaction with cadmium for instance by post-
translational modifications (PTM) or oxidation. When a total population
of ERa is exposed to cadmium, the metal binds close the ligand binding
pocket of unmodified ERa and prevents the formation of active
conformation recognized by AF-2 interacting co-activators, but in the
case of modified ERa (the diamond indicates modification of the
cysteine residues) cadmium binds outside the ligand binding pocket
and pulls the receptor towards the active conformation that allows
interaction with co-activators. (B) In living cells, membrane-associated
ERa and nuclear unmodified ERa could be examples of receptor pools
with different reactivity towards cadmium.
doi:10.1371/journal.pone.0023048.g005
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reactivity towards cadmium (Figure 5A). This could lead to a
hypothetical scenario where, for instance, palmitoylated ERa at
the membranes is stimulated by cadmium whilst nuclear,
unmodified is not (Figure 5B). Interestingly, support for this
hypothetical model comes from two independent recent reports
that have studied the effects of cadmium on both rapid, membrane
associated estrogen signaling as well as on the nuclear estrogen
signaling. Using human breast cancer cells, Zang et al. showed
that cadmium promotes rapid ERK1/2 phosphorylation, which is
a typical membrane associated estrogen effect, while not having an
effect on the transcription of estrogen target genes pS2 and PgR
[19]. Essentially the same pattern of activity was observed in vivo in
mice by Ali and coworkers: they treated estrogen reporter mice
with CdCl2 and observed phosphorylation of ERK1/2 in liver but
no effects on transcriptional activity of the nuclear ERa [26]. It is
worth noting that under suitable conditions extranuclear kinase
activation can lead to transactivation of nuclear ERa [44]. The
possible differing responsiveness of distinct cellular ERa pools to
cadmium, combined with the inherent connection between the
extranuclear and nuclear estrogen signaling, could help to explain
some of the contradicting results on the estrogenicity of cadmium.
Future studies should vigorously test our working hypothesis by
examining the effect of post-translational modifications and
oxidative stress on the responsiveness of ERa towards cadmium
in the nuclear and extranuclear parts of the estrogen signaling
pathway.
Supporting Information
Figure S1 Surface chemistry reaction scheme. Two
differently functionalized transducers were used. Both were
prepared in the same way for the first two steps: 1) Coupling of
3-glycidyloxypropyl-trimethoxysilane to the activated surface (in
acetone for 1 h at room temperature) followed by 2) coupling of
DAPEG (in dichloromethane for 18 h at 70uC). The transducers
were then either 3) covalently modified with E117-CMO (in DMF
for 6 h at room temperature) using diisopropylcarbodiimide
activation or 4) covalently modified with biotin (in DMF for 1 h
at room temperature). The biotin-modified transducers were then
put into the RIfS setup and rinsed with 5) Streptavin (1 mg/mL
for 250 s at room temperature) and subsequently rinsed with 6)
biotinylated a/b I peptide solution (1 mg/mL for 250 s at room
temperature). The last two steps were also monitored online using
RIfS.
(TIF)
Figure S2 Ligand binding assay scheme. A constant
amount of hERa (548 nM for hERa and 208.3 nM for CM-
hERaLBD) is incubated with different concentrations of estrogenic
ligands (top row). With increasing amount of estrogenic ligand the
binding of the receptor to the transducer chip is inhibited,
resulting in a smaller increase in optical thickness and smaller
relative slope. By plotting the relative slope values as a function of
ligand concentration, and applying a non-linear fit (described in
detail in the materials and methods section), the affinity of the
ligand towards the receptor can be calculated.
(TIF)
Figure S3 Conformation assay scheme. A constant amount
of hERa (3.3 mM) is incubated with either E2 (33 mM) or 4-OHT
(24 mM) in the presence or absence of CdCl2 (3.3 mM). After the
incubation phase of 1 h at 4uC, helix 12 of the receptor LBD is
either in a typically agonistic conformation (symbolized by the
cylinder in the green receptor, right) or in an antagonistic
conformation (symbolized by the cylinder in the red receptor, left).
When rinsing these mixtures over the a/b I modified transducer
chip and monitoring the optical thickness as a function of time, the
different conformations result in the different binding curves
(higher green curve for agonists and lower red curve for
antagonist) in RIfS.
(TIF)
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